(:PDLI)
Business Focus: N/A
Dec 14, 2020 07:30 am ET
PDL BioPharma Enters into $51.4 Million Capital Provision Agreement with Epps Investments LLC Regarding PDL's Previously Announced Settlement Agreement with Wellstat
RENO, Nev., Dec. 14, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces it has entered into a Capital Provision Agreement (the "Agreement") with Epps Investments LLC ("Epps"). Under the terms of the Agreement, Epps will pay PDL $51,391,184 no later than December 31, 2020, in exchange for 100% of the payments or other property or value received by PDL on or after the date of the Agreement pursuant to the settlement agreement (the "Settlement Agreement") with related entities of Defined Diagnostics, LLC (f/k/a Wellstat Diagnostics, LLC) ("Wellstat Diag
Dec 08, 2020 03:05 pm ET
PDL Announces Timeline for Voluntarily Delisting from Nasdaq
INCLINE VILLAGE, Nev., Dec. 8, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has formally notified The Nasdaq Stock Market, Inc. of its intent to delist the Company's common stock from the Nasdaq Global Select Market ("Nasdaq"). PDL expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the voluntary delisting of its common stock on or about December 28, 2020 and to suspend trading of its common stock on the Nasdaq Global Select Market prior to
Nov 11, 2020 03:05 pm ET
PDL BioPharma Reports 2020 Third Quarter Financial Results and Sets Date To File a Certificate of Dissolution
INCLINE VILLAGE, Nev., Nov. 11, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2020 and provides an update on important milestones achieved in the execution of its monetization and liquidation plan.
Nov 06, 2020 04:26 pm ET
PDL BioPharma Reschedules Third Quarter 2020 Financial Results and Business Update
INCLINE VILLAGE, Nev., Nov. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces it has rescheduled the date for announcing third quarter 2020 financial results and holding a conference call to Wednesday, November 11, 2020. PDL will issue its third quarter 2020 financial results news release on November 11 after market close, and PDL's management will host a conference call and webcast that same day at 4:30 p.m. Eastern time to discuss those financial results and provide an update on its progress in monetizing the Company's assets. A slide presentat
Oct 29, 2020 08:00 am ET
PDL BioPharma to Announce Third Quarter 2020 Financial Results and Provide a Business Update on November 9, 2020
INCLINE VILLAGE, Nev., Oct. 29, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its third quarter 2020 financial results for the period ended September 30, 2020, on Monday, November 9, 2020 after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss financial results and provide an update on its progress in monetizing the Company's assets. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
Aug 06, 2020 04:05 pm ET
PDL BioPharma Reports 2020 Second Quarter Financial Results
INCLINE VILLAGE, Nev., Aug. 6, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2020 and provides an update on important milestones achieved in the execution of its monetization plan:
Jul 30, 2020 04:05 pm ET
PDL BioPharma to Announce Second Quarter 2020 Financial Results on August 6, 2020
INCLINE VILLAGE, Nev., July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its second quarter 2020 financial results for the period ended June 30, 2020, on Thursday, August 6, 2020, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
Jul 30, 2020 08:30 am ET
PDL BioPharma Enters Into Agreement for the Divestiture of the Noden Pharmaceutical Business to Stanley Capital
INCLINE VILLAGE, Nev., July 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing of a definitive agreement for the sale of 100% of the outstanding stock in its wholly owned subsidiaries Noden Pharma DAC and Noden USA (collectively "Noden") to Stanley Capital ("Stanley Capital"). The total value of the transaction will result in payments to PDL of up to $48.25 million in cash.
May 21, 2020 04:05 pm ET
PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders
INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces that it has completed its previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM), which represented approximately 26.7% of the outstanding shares of Evofem common stock as of the close of business on May 15, 2020 (the "record date").
May 18, 2020 04:05 pm ET
PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders
INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the final distribution ratio for the previously announced distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM) to be made on May 21, 2020 (the "distribution date"). Based on the shares of PDL common stock outstanding as of the close of business on May 15, 2020 (the "record date"), PDL stockholders of record as of the record date will be entitled to receive 0.11591985 shares of Evofem common stock
May 07, 2020 04:05 pm ET
PDL BioPharma Reports 2020 First Quarter Financial Results
INCLINE VILLAGE, Nev., May 7, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three months ended March 31, 2020 and provides a business update:
May 05, 2020 04:05 pm ET
PDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders
INCLINE VILLAGE, Nev., May 5, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that the Company's Board of Directors has approved a distribution of all of the Company's 13,333,334 shares of common stock of Evofem Biosciences, Inc. ("Evofem") (Nasdaq: EVFM) via a special one-time dividend to PDL stockholders.
Apr 30, 2020 08:30 am ET
PDL BioPharma to Announce First Quarter 2020 Financial Results on May 7, 2020
INCLINE VILLAGE, Nev., April 30, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period ended March 31, 2020, on Thursday, May 7, 2020, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
Nov 14, 2019 07:56 am ET
PDL BioPharma Reaffirms Commitment To Shareholder Value Creation
INCLINE VILLAGE, Nev., Nov. 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today issued the following statement in response to Engine Capital LP's ("Engine") escalation of its public campaign criticizing PDL's strategic direction:
Nov 14, 2019 06:00 am ET
Engine Capital Releases Presentation To Board Of PDL BioPharma
NEW YORK, Nov. 14, 2019 /PRNewswire/ -- Engine Capital LP (together with its affiliates, "Engine"), a significant shareholder of PDL BioPharma, Inc. ("PDLI" or the "Company") (Nasdaq: PDLI), with ownership of approximately 5.3% of the Company's outstanding shares, announced today that it has publicly released a presentation to the Board of Directors of the Company. The presentation highlights why the Company's current strategy is flawed and resulted in PDLI's stock trading at one of its widest discounts to book value prior to Engine filing its Schedule 13D on October 23, 2019. The presentati
Nov 06, 2019 03:05 pm ET
PDL BioPharma Reports 2019 Third Quarter Financial Results
INCLINE VILLAGE, Nev., Nov. 6, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and nine months ended September 30, 2019:
Oct 30, 2019 09:00 am ET
PDL BioPharma to Announce Third Quarter 2019 Financial Results on November 6, 2019
INCLINE VILLAGE, Nev., Oct. 30, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter 2019 financial results for the period ended September 30, 2019, on Wednesday, November 6, 2019, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
Oct 24, 2019 10:06 pm ET
PDL BioPharma Responds to Letter from Engine Capital
INCLINE VILLAGE, Nev., Oct. 24, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that Harold E. Selick, Ph.D., Chairman of the Board of Directors of PDL BioPharma, has sent the following letter to Engine Capital, LP.
Oct 23, 2019 07:00 am ET
Engine Capital Issues Open Letter to Board of PDL BioPharma
NEW YORK, Oct. 23, 2019 /PRNewswire/ -- Engine Capital LP (together with its affiliates, "Engine"), a significant shareholder of PDL BioPharma, Inc. (the "Company") (NASDAQ:PDLI), with ownership of approximately 5.3% of the Company's outstanding shares, today issued an open letter to the Company's Board of Directors (the "Board") encouraging the Company to immediately cease its investment activities and commence a review of strategic alternatives, including a possible sale or liquidation of the Company.
Sep 26, 2019 09:00 am ET
PDL BioPharma to Participate in the 2019 Cantor Fitzgerald Global Healthcare Conference
INCLINE VILLAGE, Nev., Sept. 26, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Friday, October 4, 2019, at 1:10 p.m. Eastern time (10:10 a.m. Pacific time). The conference is being held at the Intercontinental New York Barclay Hotel.
Sep 12, 2019 10:20 pm ET
PDL BioPharma Announces Private Exchange of Approximately $86.1 Million of Convertible Notes Due 2024
INCLINE VILLAGE, Nev., Sept. 12, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) today announced that it has entered into separate privately negotiated transactions to exchange approximately $86.1 million in aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the "Existing Notes") for approximately $86.1 million in aggregate original principal amount of new 2.75% Convertible Senior Notes due 2024 (the "Exchange Notes" and such transaction, the "Exchange") together with an aggregate of approximately $6.0 million of cash. Following the
Sep 11, 2019 10:44 pm ET
PDL BioPharma Announces Favorable Decision in Wellstat Diagnostics Litigation
INCLINE VILLAGE, Nev., Sept. 11, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announced that the Supreme Court of New York, County of New York, Commercial Division, issued its decision today in PDL's previously disclosed litigation related to defaults by Wellstat Diagnostics on loans made to it by the Company. The loans of $44,100,000 were made pursuant to a loan agreement between Wellstat Diagnostics and PDL dated August 2013. Today's decision resolved a dispute regarding the validity and enforceability of guarantees on the loan made by related entities
Aug 07, 2019 04:18 pm ET
PDL BioPharma Reports 2019 Second Quarter Financial Results
INCLINE VILLAGE, Nev., Aug. 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) reports financial results for the three and six months ended June 30, 2019:
Aug 05, 2019 04:10 pm ET
Evofem Biosciences Reports Second Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, Aug. 5, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical company, today reported financial results for the three- and six- month period ended June 30, 2019. Second quarter and recent highlights include:
Jul 31, 2019 09:00 am ET
PDL BioPharma to Announce Second Quarter 2019 Financial Results on August 7, 2019
INCLINE VILLAGE, Nev., July 31, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its second quarter 2019 financial results for the period ended June 30, 2019, on Wednesday, August 7, 2019, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.
May 15, 2019 09:00 am ET
PDL BioPharma to Participate at UBS Global Healthcare Conference
INCLINE VILLAGE, Nev., May 15, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at the UBS Global Healthcare Conference in New York City. The session will be webcast live and will occur on Tuesday, May 21, 2019, at 8:30 a.m. Eastern time (5:30 a.m. Pacific time).
May 09, 2019 04:05 pm ET
PDL BioPharma Reports 2019 First Quarter Financial Results
INCLINE VILLAGE, Nev., May 9, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three months ended March 31, 2019:
May 07, 2019 06:00 am ET
Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update
SAN DIEGO, May 7, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical company, today reported financial results for the three- month period ended March 31, 2019. First quarter and recent highlights include:
May 02, 2019 09:00 am ET
PDL BioPharma to Announce First Quarter 2019 Financial Results on May 9, 2019
INCLINE VILLAGE, Nev., May 2, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its first quarter 2019 financial results for the period ended March 31, 2019, on Thursday, May 9, 2019, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com.
Apr 16, 2019 04:05 pm ET
PDL BioPharma to Hold Annual Meeting of Stockholders on June 20, 2019
INCLINE VILLAGE, Nev., April 16, 2019 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, June 20, 2019, at 3:00 p.m. Pacific Time for all stockholders of record on April 26, 2019. The meeting will take place at The Chateau at Incline Village in Incline Village, Nev.
Apr 11, 2019 10:25 am ET
PDL BioPharma Announces Equity Investment in Evofem Biosciences
INCLINE VILLAGE, Nev., April 11, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that it has entered into a securities purchase agreement with Evofem Biosciences, Inc. ("Evofem") (NASDAQ: EVFM), pursuant to which it will invest a total of up to $60 million in a private placement of securities. The transaction is expected to have two tranches. The first tranche comprises $30 million, which was provided today. In addition, PDL has the right to invest an additional $30 million in a second tranche alongside two existing Evofem shareholders, which hav
Apr 11, 2019 10:19 am ET
Evofem Biosciences Enters into Financing Agreement for up to $80 Million, Closes First Tranche of Strategic Investment from PDL BioPharma
SAN DIEGO, April 11, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) ("Evofem"), today announced it has entered into a securities purchase agreement pursuant to which Evofem can raise up to $80 million through a private placement of common stock from new and existing investors, including a strategic investment from PDL BioPharma, Inc. (NASDAQ: PDLI) ("PDL").
Apr 09, 2019 08:10 am ET
New Research: Key Drivers of Growth for PDL BioPharma, Teekay LNG Partners, Atlantic Power, Chaparral Energy, Encore Capital Group, and Universal Electronics — Factors of Influence, Major Initiatives
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of PDL BioPharma, Inc. (NASDAQ:PDLI), Teekay LNG Partners L.P. (NYSE:TGP),...
Mar 26, 2019 09:00 am ET
PDL BioPharma to Participate at H.C. Wainwright & Co. Global Life Sciences Conference
INCLINE VILLAGE, Nev., March 26, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London. The session will be webcast live and will occur on Tuesday, April 9, 2019, at 10:50 a.m. British Standard Time.
Mar 14, 2019 04:05 pm ET
PDL BioPharma Reports 2018 Fourth Quarter and Full Year Financial Results
INCLINE VILLAGE, Nev., March 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and 12 months ended December 31, 2018:
Mar 12, 2019 09:00 am ET
PDL BioPharma to Participate at 31st Annual Roth Conference
INCLINE VILLAGE, Nev., March 12, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Peter Garcia, PDL's vice president and chief financial officer, will participate in a series of investor meetings at the 31st Annual Roth Conference being held March 17-19 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif. Mr. Garcia will also participate in a panel entitled "Searching for Deep Value in Pharma" being held on March 19 at 10:00 a.m. Pacific time.
Mar 07, 2019 08:00 am ET
PDL BioPharma to Announce 2018 Fourth Quarter and Full Year Financial Results on March 14, 2019
INCLINE VILLAGE, Nev., March 7, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018, on Thursday, March 14, 2019, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m., Eastern time, to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com.
Mar 05, 2019 03:05 pm ET
PDL BioPharma to Participate at Cowen 39th Annual Health Care Conference
INCLINE VILLAGE, Nev., March 5, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at the Cowen 39th Annual Health Care Conference in New York City. The session will be webcast live and will occur on Tuesday, March 12, 2019, at 12:00 p.m. Eastern time (9:00 a.m. Pacific time).
Mar 04, 2019 03:05 pm ET
PDL BioPharma Announces Launch of an Authorized Generic of Tekturna® (aliskiren) in Partnership with Prasco Laboratories
INCLINE VILLAGE, Nev., March 4, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL", NASDAQ: PDLI) announces the U.S. commercial launch of an authorized generic of Tekturna®, aliskiren hemifumarate 150 mg and 300 mg tablets. The authorized generic has the same drug formulation as Tekturna. The launch is being carried out by Prasco, LLC, d/b/a Prasco Laboratories, under an agreement with PDL's wholly owned subsidiary, Noden Pharma USA, Inc. ("Noden").
Nov 30, 2018 08:15 am ET
Report: Exploring Fundamental Drivers Behind Tesla, Nordson, Paycom Software, PDL BioPharma, Corcept Therapeutics, and Willis Towers Watson Public — New Horizons, Emerging Trends, and Upcoming Develop
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Tesla, Inc. (NASDAQ:TSLA), Nordson Corporation (NASDAQ:NDSN), Paycom...
Nov 19, 2018 08:00 am ET
PDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
INCLINE VILLAGE, Nev., Nov. 19, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare Conference in New York City. The session will be webcast live and will occur on Tuesday, November 27, 2018, at 1:50 p.m. EST.
Nov 06, 2018 03:05 pm ET
PDL BioPharma Reports Third Quarter 2018 Financial Results
INCLINE VILLAGE, Nev., Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including:
Oct 31, 2018 04:05 pm ET
PDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018
INCLINE VILLAGE, Nev., Oct. 31, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018, on Tuesday, November 6, 2018, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m., Eastern time, to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com.
Oct 23, 2018 07:45 am ET
Report: Exploring Fundamental Drivers Behind The Home Depot, uniQure N.V, Catalent, Apple, BioTime, and PDL BioPharma — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Home Depot, Inc. (NYSE:HD), uniQure N.V. (NASDAQ:QURE), Catalent, Inc....
Oct 08, 2018 09:00 am ET
PDL BioPharma Names Edward Imbrogno Vice President of Finance
INCLINE VILLAGE, Nev., Oct. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position. Mr. Imbrogno brings to PDL more than 30 years of public accounting and financial reporting experience and will report to Vice President and Chief Financial Officer, Peter Garcia.
Sep 26, 2018 09:00 am ET
PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
INCLINE VILLAGE, Nev., Sept. 26, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin, PDL's chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York City. The session will be webcast live and will occur on Wednesday, October 3, 2018, at 12:15pm EDT.
Sep 24, 2018 09:00 am ET
PDL BioPharma Announces New $100 Million Stock Repurchase Program
INCLINE VILLAGE, Nev., Sept. 24, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock. Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission.
Sep 20, 2018 08:30 am ET
SevenSaoi Capital Delivers Letter to the Board of PDL BioPharma
CHICAGO, Sept. 20, 2018 /PRNewswire/ -- SevenSaoi Capital, LLC (together with its affiliates, "SevenSaoi," pronounced "7C"), a long-only public equity investment firm and significant shareholder in PDL BioPharma, Inc. (NasdaqGS: PDLI) ("PDL" or the "Company") with 2,590,198 shares of common stock, announced today that it has delivered a letter to the Board of Directors of PDL. The letter, which can be accessed below, addresses SevenSaoi's serious concerns with the Company's failed acquisition strategy and calls upon the Board to authorize a large share repurchase for the benefit of all share
Aug 30, 2018 08:00 am ET
PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
INCLINE VILLAGE, Nev., Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin, PDL's chief executive officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference next week in New York City. The session will be webcast live and will occur on Thursday, September 6, 2018, at 2:35 p.m. EDT.
Aug 28, 2018 08:20 am ET
Report: Developing Opportunities within Parker Drilling, CoreLogic, Steven Madden, Diebold Nixdorf, Nevro, and PDL BioPharma — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Parker Drilling Company (NYSE:PKD), CoreLogic, Inc. (NYSE:CLGX), Steven...
Aug 08, 2018 04:05 pm ET
PDL BioPharma Reports Second Quarter 2018 Financial Results
INCLINE VILLAGE, Nev., Aug. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) reports financial results for the three and six months ended June 30, 2018 including:
Aug 02, 2018 04:02 pm ET
PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products
INCLINE VILLAGE, Nev., Aug. 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the "Royalty Agreement") with Depomed, Inc. ("Depomed") under which PDL acquired all of Depomed's remaining rights to royalties and milestones payable on sales of type 2 diabetes products licensed by Depomed for up to $20 million. Under the original Royalty Agreement PDL would have shared future royalties equally with Depomed after total cash received by PDL reached $481 million, or two times PDL's original investment, which PDL ex
Aug 01, 2018 09:00 am ET
PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018
INCLINE VILLAGE, Nev., Aug. 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2018, on Wednesday, August 8, 2018, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Jun 26, 2018 07:40 am ET
Research Report Identifies PDL BioPharma, TEGNA, Patterson Companies, Boardwalk Pipeline Partners, Exact Sciences, and Berkshire Hathaway with Renewed Outlook — Fundamental Analysis, Calculating Forwa
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of PDL BioPharma, Inc. (NASDAQ:PDLI), TEGNA Inc. (NYSE:TGNA), Patterson...
Jun 22, 2018 09:00 am ET
Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors
INCLINE VILLAGE, Nev., June 22, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth G. O'Farrell has been named to the Company's Board of Directors, effective June 22, 2018 and increasing the number of directors to nine.
Jun 11, 2018 09:00 am ET
Shlomo Yanai Elected to PDL BioPharma's Board of Directors
INCLINE VILLAGE, Nev., June 11, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced that at its 2018 annual meeting of stockholders held June 8, 2018, the Company's stockholders elected Shlomo Yanai to the Company's Board of Directors. The Company announced that its stockholders also voted to re-elect Jody Lindell and John McLaughlin as Directors, approve an amended and restated equity plan and approve, on an advisory basis, executive officer compensation.
May 21, 2018 09:00 am ET
PDL BioPharma Names Dr. Jill Jene Vice President, Business Development
INCLINE VILLAGE, Nev., May 21, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announces the appointment of Jill M. Jene, Ph.D. as Vice President, Business Development. Dr. Jene will lead the efforts to add healthcare assets to PDL's portfolio of products and companies. She will report to PDL President, Dominique Monnet.
May 15, 2018 07:00 am ET
PDL BioPharma to Present at Two Upcoming Investor Conferences
INCLINE VILLAGE, Nev., May 15, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will present at the following two upcoming investor conferences:
May 09, 2018 04:01 pm ET
PDL BioPharma Announces First Quarter 2018 Financial Results
INCLINE VILLAGE, Nev., May 9, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2018 including:
May 08, 2018 08:30 am ET
Investor Expectations to Drive Momentum within Masco, Murphy Oil, NGL Energy Partners LP, PBF Energy, PDL BioPharma, and Phillips 66 — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Masco Corporation (NYSE:MAS), Murphy Oil Corporation (NYSE:MUR), NGL...
May 02, 2018 07:00 am ET
PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018
INCLINE VILLAGE, Nev., May 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it will release its first quarter 2018 financial results for the period ended March 31, 2018, on Wednesday, May 9, 2018, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Apr 16, 2018 07:00 am ET
PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018
INCLINE VILLAGE, Nev., April 16, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June 8, 2018, at 10:00 a.m. Pacific Time for all stockholders of record on May 4, 2018. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.
Apr 09, 2018 04:59 pm ET
PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Delivers Letter to the Board Outlining Significant Concerns
CHICAGO, April 9, 2018 /PRNewswire/ -- SevenSaoi Capital, LLC (together with its affiliates, "SevenSaoi," pronounced "7C"), a long-only public equity investment firm that owns 2,590,198 shares of common stock of PDL BioPharma, Inc. (NasdaqGS: PDLI) ("PDL" or the "Company"), is pleased that, following SevenSaoi's nomination of Shlomo Yanai to the PDL Board, the Company has added Mr. Yanai to its slate of director nominees for PDL's 2018 Annual Meeting. SevenSaoi introduced and nominated Mr. Yanai to the PDL Board as part of a slate of highly-qualified director candidates in March 2018. Since
Apr 03, 2018 04:02 pm ET
PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference
INCLINE VILLAGE, Nev., April 3, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that Peter Garcia, PDL's vice president and chief financial officer, will present at the H.C. Wainwright Global Life Sciences Conference next week in Monaco. The session will be webcast live and will occur on Tuesday, April 10, 2018 at 1:45 p.m. CEST.
Mar 08, 2018 03:02 pm ET
PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results
INCLINE VILLAGE, Nev., March 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2017 including:
Mar 07, 2018 07:45 am ET
Report: Developing Opportunities within Seattle Genetics, PBF Energy, Chipotle Mexican Grill, CIT Group Inc (DEL), PDL BioPharma, and Dollar General — Future Expectations, Projections Moving into 2018
NEW YORK, March 07, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Seattle Genetics, Inc. (NASDAQ:SGEN), PBF Energy...
Mar 01, 2018 06:00 am ET
PDL BioPharma to Announce Fourth Quarter / Year-End 2017 Financial Results on March 8, 2018
INCLINE VILLAGE, Nev., March 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2017 financial results for the period ended December 31, 2017, on Thursday March 8, 2018, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Feb 26, 2018 11:16 am ET
Richard L. Lindstrom, M.D. Joins LENSAR, Inc. Board of Directors
LENSAR, Inc., an emerging leader in next generation femtosecond laser
technology for refractive cataract surgery, today is pleased to announce
world renowned ophthalmologist Richard L. Lindstrom, M.D. has joined the
company’s board of directors effective immediately.
Feb 20, 2018 08:56 am ET
Neos Therapeutics Reiterates Confidence in Strategic Plan and Value Creation Opportunities
DALLAS and FORT WORTH, Texas, Feb. 20, 2018 /PRNewswire/ -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, issued the following statement in response to the announcement from PDL BioPharma, Inc. (NASDAQ: PDLI) that it is terminating its interest in the Company:
Feb 20, 2018 06:00 am ET
PDL BioPharma Terminates Interest in Pursuing Acquisition of Neos
INCLINE VILLAGE, Nev., Feb. 20, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today officially announced it will no longer pursue its proposed acquisition of Neos Therapeutics, Inc. (NASDAQ: NEOS). While PDL's last public disclosure announced its proposal expired on November 8, 2017, PDL has maintained its interest until recently making the decision to not make any further proposals.
Feb 14, 2018 06:00 am ET
PDL BioPharma to Present at Two Upcoming Investor Conferences
INCLINE VILLAGE, Nev., Feb. 14, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's chief executive officer, will present at the following two upcoming investor conferences:
Nov 15, 2017 10:36 am ET
Noden Pharma Announces FDA Approval of Tekturna®(aliskiren) Oral Pellets for the Treatment of Hypertension in Adults and Children 6 Years of Age and Older
DUBLIN, Nov. 15, 2017 /PRNewswire/ -- Noden Pharma DAC, a global specialty pharmaceutical company that is focused on acquiring prescription medicines across a broad range of therapeutic areas, announced today the approval by the U.S. Food and Drug Administration of Tekturna®(aliskiren) Oral Pellets for the treatment of hypertension in adults and children six years of age and older. The new formulation and pediatric indication were approved through the FDA priority review process. Noden Pharma DAC is a wholly-owned subsidiary of PDL BioPharma, Inc. (Nasdaq: PDLI).
Nov 09, 2017 08:20 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Tegna, Inpixon, Honeywell International, Nektar, PDL Biopharma, and Innoviva – New Research Emphasizes Economic Growth
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tegna Inc. (NYSE:TGNA), Inpixon (NASDAQ:INPX), Honeywell...
Nov 08, 2017 08:00 am ET
PDL BioPharma's Proposal to Acquire Neos Therapeutics Expires Today; PDL Urges Neos to Provide Update on Sale Process
INCLINE VILLAGE, Nev., Nov. 8, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) reiterated that its proposal to acquire Neos Therapeutics, Inc. (NASDAQ: NEOS) for $10.25 per share in cash will expire today at market close. PDL originally made public its proposal to acquire Neos on October 26, 2017 at a premium of approximately 40 percent to the pre-proposal closing price of Neos shares.
Nov 07, 2017 04:02 pm ET
PDL BioPharma to Present at Two Upcoming Investor Conferences
INCLINE VILLAGE, Nev., Nov. 7, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in November.
Nov 02, 2017 05:02 pm ET
PDL BioPharma Announces Third Quarter 2017 Financial Results
INCLINE VILLAGE, Nev., Nov. 2, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2017 including:
Oct 30, 2017 05:38 pm ET
PDL BioPharma Issues Statement in Response to Neos Therapeutics Rejection of PDL Acquisition Proposal
INCLINE VILLAGE, Nev., Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today issued the following statement in response to the Neos Therapeutics, Inc. ("Neos") (NASDAQ: NEOS) Board of Directors' rejection of PDL's October 26 proposal to acquire Neos for $10.25 per share in cash:
Oct 30, 2017 09:30 am ET
Neos Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from PDL BioPharma
DALLAS and FORT WORTH, Texas, Oct. 30, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today announced that its Board of Directors has unanimously rejected the October 26 unsolicited proposal from PDL BioPharma, Inc. (NASDAQ: PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash.
Oct 30, 2017 08:00 am ET
PDL BioPharma Announces Settlement Agreement with Valeant
INCLINE VILLAGE, Nevada, Oct. 30, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) today announced that on October 27, 2017, PDL and Depomed, Inc. ("Depomed") entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. and its indirect subsidiary Valeant Pharmaceuticals Luxembourg S.à r.l. (together, "Valeant") that resolves all matters addressed in the lawsuit filed by Depomed on September 7, 2017 relating to alleged underpayment of royalties by Valeant (the "Settlement Agreement"). Under the terms of the Settlement Agreement, the pa
Oct 26, 2017 11:01 am ET
Neos Therapeutics to Review Unsolicited Proposal from PDL BioPharma
DALLAS and FORT WORTH, Texas, Oct. 26, 2017 /PRNewswire/ -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technologies, today confirmed that it has received an unsolicited proposal from PDL BioPharma, Inc. (NASDAQ: PDLI) to acquire all of the outstanding shares of Neos for $10.25 per share in cash.
Oct 26, 2017 09:30 am ET
PDL BioPharma Proposes to Acquire Neos Therapeutics for $10.25 per Share in Cash
INCLINE VILLAGE, Nev., Oct. 26, 2017 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it has submitted a proposal to acquire Neos Therapeutics, Inc. ("Neos") (NASDAQ: NEOS) for $10.25 per share in cash. This all-cash transaction represents a premium of 40% to the closing price of Neos shares on October 25, 2017 and a premium of 41% to Neos' share price prior to PDL's initial proposal on June 23, 2017. The PDL proposal is not subject to any financing conditions.
Oct 25, 2017 05:45 pm ET
PDL BioPharma to Announce Third Quarter 2017 Financial Results on November 2, 2017
INCLINE VILLAGE, Nev., Oct. 25, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter financial results for the period ended September 30, 2017, on Thursday, November 2, 2017, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Sep 25, 2017 08:00 am ET
PDL BioPharma Announces New $25 Million Share Repurchase Program
INCLINE VILLAGE, Nev., Sept. 25, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) announced today that PDL's board of directors has authorized a new stock repurchase program to acquire up to $25 million of the Company's common stock. Purchases may be made in open-market transactions, block transactions on or off an exchange, in privately negotiated transactions, or other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission.
Sep 19, 2017 08:00 am ET
PDL BioPharma Updates Presentation Time for Cantor Fitzgerald Conference
INCLINE VILLAGE, Nev., Sept. 19, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's chief executive officer, will present at the 2017 Cantor Fitzgerald Global Healthcare Conference in New York City on Tuesday, September 26, 2017, at 10:20 a.m. EDT. PDL's presentation was originally scheduled for September 25th but was subsequently moved to the 26th.
Sep 11, 2017 05:02 pm ET
PDL BioPharma Appoints Dominique Monnet as President
INCLINE VILLAGE, Nev., Sept. 11, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company has appointed Dominique P. Monnet to the position of president. Mr. Monnet brings over 30 years of international business experience in the biotechnology / pharmaceutical industry. He will report into PDL's chief executive officer, John McLaughlin.
Sep 06, 2017 08:00 am ET
PDL BioPharma to Present at Two Upcoming Investor Conferences
INCLINE VILLAGE, Nev., Sept. 6, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in September.
Aug 03, 2017 05:02 pm ET
PDL BioPharma Announces Second Quarter 2017 Financial Results
INCLINE VILLAGE, Nev., Aug. 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2017 including:
Jul 31, 2017 08:00 am ET
PDL BioPharma to Announce Second Quarter 2017 Financial Results on August 3, 2017
INCLINE VILLAGE, Nev., July 31, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter financial results for the period ended June 30, 2017, on Thursday, August 3, 2017, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Jun 05, 2017 08:00 am ET
Noden Pharma Notified of ANDA Filing for Tekturna®
INCLINE VILLAGE, N.V., June 5, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that its subsidiary, Noden Pharma DAC (Noden), received a Paragraph IV Notice Letter advising that Anchen Pharmaceuticals, Inc. (Anchen) submitted an Abbreviated New Drug Application ("ANDA") to the United States Food and Drug Administration (FDA) seeking authorization from the FDA to manufacture and market a generic version of Tekturna ® aliskiren hemifumarate tablets, 150 mg and 300 mg, in the United States.
Jun 01, 2017 08:00 am ET
PDL BioPharma to Present at the Jefferies 2017 Healthcare Conference
INCLINE VILLAGE, Nev., June 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that Peter Garcia, the company's vice president and chief financial officer, will present at the Jefferies 2017 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Friday, June 9, 2017 at 8:30 a.m. EDT. John McLaughlin, PDL's president and chief executive officer, will not attend the conference given that the company's Annual Meeting of Stockholders is scheduled for the same day in Incline Village, NV.
May 11, 2017 08:00 am ET
LENSAR® And PDL BioPharma Complete Strategic Financial Restructuring Of LENSAR
ORLANDO, Fla., and INCLINE VILLAGE, Nev., May 11, 2017 /PRNewswire/ -- LENSAR, Inc. (LENSAR), a global leader in next generation femtosecond laser technology for refractive cataract surgery, and PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced the completion of LENSAR's financial restructuring with a court-approved exit plan finalized on May 11, 2017. As part of the plan, PDL will convert most of its debt to an equity ownership position. LENSAR will become a wholly-owned subsidiary of PDL, and PDL will begin to consolidate LENSAR's financial statements.
May 03, 2017 05:02 pm ET
PDL BioPharma Announces First Quarter 2017 Financial Results
INCLINE VILLAGE, Nev., May 3, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2017 including:
Apr 26, 2017 08:00 am ET
PDL BioPharma to Announce First Quarter 2017 Financial Results on May 3, 2017
INCLINE VILLAGE, Nev., April 26, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2017 financial results for the period ended March 31, 2017, on Wednesday, May 3, 2017, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Apr 24, 2017 08:00 am ET
PDL BioPharma Announces Settlement of Keytruda Patent Infringement Lawsuit with Merck
INCLINE VILLAGE, Nev., April 24, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that on April 21, 2017, the Company entered into a settlement agreement with certain subsidiaries of Merck & Co., Inc. ("Merck") to resolve the patent infringement lawsuit between the parties pending in the U.S. District Court for the District of New Jersey related to Merck's Keytruda humanized antibody product. Under the terms of the agreement, Merck will pay the Company a one time, lump-sum payment of $19.5 million, and the Company will grant Merck a fully paid-
Apr 06, 2017 05:02 pm ET
PDL BioPharma to Hold Annual Meeting of Stockholders on June 9, 2017
INCLINE VILLAGE, Nev., April 6, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June 9, 2017, at 10:00 a.m. Pacific Time for all stockholders of record on April 17, 2017. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.
Mar 14, 2017 08:00 am ET
PDL BioPharma to Present at the Oppenheimer 27th Annual Healthcare Conference
INCLINE VILLAGE, Nev., March 14, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at the Oppenheimer 27th Annual Healthcare Conference next week in New York. The session will be webcast live and will occur on Tuesday, March 21, 2017 at 8:35 a.m. EDT.
Mar 02, 2017 07:00 am ET
PDL BioPharma to Present at Two Upcoming Investor Conferences
INCLINE VILLAGE, Nev., March 2, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will present at two investor conferences in March.
Mar 01, 2017 04:02 pm ET
PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results
INCLINE VILLAGE, Nev., March 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the fourth quarter and year ended December 31, 2016 including:
Mar 01, 2017 07:00 am ET
PDL BioPharma Announces $30 Million Share Repurchase Program
INCLINE VILLAGE, Nev., March 1, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that the company's board of directors has authorized the repurchase of up to $30 million of the company's common stock through March 2018. Purchases may be made in open-market transactions, block transactions on or off an exchange, in privately negotiated transactions, or other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission.
Feb 22, 2017 07:00 am ET
PDL BioPharma to Announce Fourth Quarter / Year-End 2016 Financial Results on March 1, 2017
INCLINE VILLAGE, Nev., Feb. 22, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter, year-end 2016 financial results for the period ended December 31, 2016, on Wednesday, March 1, 2017, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Feb 17, 2017 07:00 am ET
PDL BioPharma to Present at the 2017 RBC Capital Markets Global Healthcare Conference
INCLINE VILLAGE, Nev., Feb. 17, 2017 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, PDL's president and chief executive officer, will participate in a fireside chat at the 2017 RBC Capital Markets Global Healthcare Conference next week in New York. The session will be webcast live and will occur on Wednesday February 22, 2017 at 2:35 p.m. EST.
Nov 22, 2016 02:44 pm ET
PDL BioPharma Issues $150.0 Million of 2.75% Convertible Senior Notes Due 2021
INCLINE VILLAGE, Nev., Nov. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today the closing of its previously announced offering of convertible senior unsecured notes due December 1, 2021 (2021 Notes). PDL issued $150.0 million aggregate principal amount of 2021 Notes. In addition, PDL has granted the underwriters an option to purchase up to an additional $22.5 million aggregate principal amount of the 2021 Notes to cover overallotments. RBC Capital Markets acted as sole book-running manager and sole structuring advisor for the 2021 Notes offering. Piper Ja
Nov 22, 2016 07:00 am ET
PDL BioPharma to Present at the 28th Annual Piper Jaffray Healthcare Conference
INCLINE VILLAGE, Nev., Nov. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 28th Annual Piper Jaffray Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, November 29, 2016 at 1:50 p.m. EST.
Nov 17, 2016 09:00 am ET
PDL BioPharma Prices Public Offering of $150.0 Million of 2.75% Convertible Senior Notes Due 2021
INCLINE VILLAGE, Nev., Nov. 17, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it has agreed to sell $150.0 million aggregate principal amount of its 2.75% Convertible Senior Notes due 2021 (the Notes) in an underwritten public offering. The conversion rate of the Notes will initially be 262.2951 shares of common stock per $1,000 principal amount of the Notes, equivalent to an initial conversion price of approximately $3.81 per share of common stock, subject to adjustment. The net proceeds from the offering, after deducting the underwriters discount and
Nov 15, 2016 04:48 pm ET
PDL BioPharma Announces Proposed $150 Million Public Offering of New Convertible Senior Notes Due 2021
INCLINE VILLAGE, Nev., Nov. 15, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced today that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1, 2021 (the Notes) under PDL's shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) on June 10, 2016 and declared effective by the SEC on June 28, 2016. RBC Capital Markets (RBC) is acting as sole book-running manager and sole structuring advisor for the Notes offering. PDL also expects to grant
Nov 03, 2016 05:02 pm ET
PDL BioPharma Announces Third Quarter 2016 Financial Results
INCLINE VILLAGE, Nev., Nov. 3, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the third quarter ended September 30, 2016 including:
Oct 27, 2016 05:02 pm ET
PDL BioPharma to Announce Third Quarter 2016 Financial Results on November 3, 2016
INCLINE VILLAGE, Nev., Oct. 27, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its third quarter 2016 financial results for the period ended September 30, 2016, on Thursday, November 3, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Aug 29, 2016 08:00 am ET
PDL BioPharma Announces the Successful Conclusion of its Debt Financing Agreement with Paradigm Spine
INCLINE VILLAGE, Nev., Aug. 29, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that PDL has received approximately $57.4 million in connection with the termination of PDL's credit agreement with Paradigm Spine, LLC, which included a repayment of the full principal amount outstanding of $54.7 million as well as accrued interest and a prepayment fee. In February 2014, PDL entered into a credit agreement with Paradigm Spine in which it made available up to $75.0 million of debt financing with a five-year term, and initially provided $50.0 million,
Aug 04, 2016 05:05 pm ET
PDL BioPharma Announces Second Quarter 2016 Financial Results
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the second quarter ended June 30, 2016 including:
Aug 04, 2016 05:02 pm ET
PDL BioPharma Announces Elimination of Quarterly Cash Dividend
INCLINE VILLAGE, Nev., Aug. 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) (PDL or the Company) today announced that its board of directors has decided to eliminate its quarterly cash dividend.
Aug 01, 2016 05:02 pm ET
PDL BioPharma Completes Second Tranche Payment Under Royalty Transaction with ARIAD Pharmaceuticals
INCLINE VILLAGE, Nev., Aug. 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has funded the second tranche of $50 million to ARIAD Pharmaceuticals, Inc. (ARIAD) (NASDAQ: ARIA) which was due on the first anniversary of the closing date under the terms of the ARIAD Royalty Agreement. This agreement was entered into in July 2015, in exchange for royalties on the net revenues of Iclusig® (ponatinib). As a result of the second tranche payment, under the terms of the ARIAD Royalty Agreement, PDL's royalty percentage will increase to 5.0% of t
Jul 28, 2016 08:00 am ET
PDL BioPharma to Announce Second Quarter 2016 Financial Results on August 4, 2016
INCLINE VILLAGE, Nev., July 28, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will release its second quarter 2016 financial results for the period ended June 30, 2016, on Thursday, August 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Jul 06, 2016 08:00 am ET
PDL BioPharma Closes Equity Investment Transaction in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
INCLINE VILLAGE, Nev., July 6, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has completed an initial equity investment of $75 million in Noden Pharma DAC (Noden), a new privately-held company domiciled in Ireland, and an affiliate. Noden today announced that it closed its transaction relating to a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HC
Jun 13, 2016 05:02 pm ET
PDL BioPharma Completes Quarterly Dividend Payment
INCLINE VILLAGE, Nev., June 13, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it has paid the June 13, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of June 6, 2016, the record date.
Jun 01, 2016 08:00 am ET
PDL BioPharma to Present at the Jefferies 2016 Healthcare Conference
INCLINE VILLAGE, Nev., June 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Jefferies 2016 Healthcare Conference next week in New York. The presentation will be webcast live and will occur on Tuesday, June 7, 2016 at 3:30 p.m. EDT.
May 24, 2016 05:02 pm ET
PDL BioPharma Commits to Equity Investment in Noden Pharma for the Acquisition of Tekturna® (aliskiren) and Tekturna HCT® (aliskiren and hydrochlorothiazide)
INCLINE VILLAGE, Nev., May 24, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that PDL has committed to an equity investment in Noden Pharma DAC, a new privately held company (Noden) that has executed a purchase agreement with Novartis AG (Novartis) to acquire exclusive worldwide rights to manufacture, market, and sell the branded prescription medicine product sold under the name Tekturna® and Tekturna HCT® in the United States and Rasilez® and Rasilez HCT® in the rest of the world. The product's active ingredient is aliskiren, which is indicated for the trea
May 04, 2016 05:02 pm ET
May 04, 2016 05:01 pm ET
PDL BioPharma Announces 2016 Second Quarter Dividend
INCLINE VILLAGE, Nev., May 4, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the second quarter of 2016. The cash dividend will be paid on June 13, 2016 to all stockholders who own shares of PDL on June 6, 2016, the record date for the second quarter dividend payment.
Apr 28, 2016 08:00 am ET
PDL BioPharma to Announce First Quarter 2016 Financial Results on May 4, 2016
INCLINE VILLAGE, Nev., April 28, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its first quarter 2016 financial results for the period ended March 31, 2016, on Wednesday, May 4, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Mar 31, 2016 05:05 pm ET
PDL BioPharma to Hold Annual Meeting of Stockholders on June 2, 2016
INCLINE VILLAGE, Nev., March 31, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, June 2, 2016, at 10:00 a.m. Pacific Time for all stockholders of record on April 8, 2016. The meeting will take place at the Hyatt Regency Hotel in Incline Village, Nevada.
Mar 14, 2016 07:00 am ET
PDL BioPharma Completes Quarterly Dividend Payment
INCLINE VILLAGE, Nev., March 14, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the March 11, 2016, quarterly dividend payment of $0.05 per share to all stockholders owning shares of PDL as of March 4, 2016, the record date.
Mar 02, 2016 07:00 am ET
PDL BioPharma to Present at the Cowen and Company 36th Annual Health Care Conference
INCLINE VILLAGE, Nev., March 2, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the Cowen and Company 36th Annual Health Care Conference next week in Boston. The presentation will be webcast live and will occur on Wednesday, March 9, 2016 at 11:20 a.m. EST.
Feb 22, 2016 04:02 pm ET
PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results
INCLINE VILLAGE, Nev., Feb. 22, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the fourth quarter and twelve months ended December 31, 2015.
Feb 17, 2016 07:00 am ET
PDL BioPharma to Present at the 2016 RBC Capital Markets' Healthcare Conference
INCLINE VILLAGE, Nev., Feb. 17, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 RBC Capital Markets' Healthcare Conference next week in New York City. The presentation will be webcast live and will occur on Wednesday, February 24, 2016 at 2:05 p.m. EST.
Feb 16, 2016 07:00 am ET
PDL BioPharma to Announce Fourth Quarter and Full Year 2015 Financial Results on February 22, 2016
INCLINE VILLAGE, Nev., Feb. 16, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company will release its fourth quarter and full year 2015 financial results for the period ended December 31, 2015, on Monday, February 22, 2016, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results. A slide presentation relating to the call will be available via the webcast link on the PDL website.
Feb 02, 2016 07:00 am ET
PDL BioPharma to Present at the 2016 BIO CEO & Investor Conference
INCLINE VILLAGE, Nev., Feb. 2, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, will present at the 2016 BIO CEO & Investor Conference next week in New York City. The presentation will be webcast live and will occur on Tuesday, February 9, 2016 at 4:00 p.m. EST.
Feb 01, 2016 04:02 pm ET
PDL BioPharma Announces 2016 First Quarter Dividend
INCLINE VILLAGE, Nev., Feb. 1, 2016 /PRNewswire/ -- PDL BioPharma, Inc. (NASDAQ: PDLI) today announced that its board of directors has declared a $0.05 per share dividend for the first quarter of 2016. The dividend will be paid on March 11, 2016 to all stockholders who own shares of PDL on March 4, 2016, the record date for the first quarter dividend payment.
Dec 14, 2015 07:00 am ET
PDL BioPharma Completes Regular Quarterly Dividend Payment
INCLINE VILLAGE, Nev., Dec. 14, 2015 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has paid the December 11, 2015, regular quarterly dividend payment of $0.15 per share to all stockholders owning shares of PDL as of December 4, 2015, the record date.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.